NYMOX PHARMACEUTICAL Business Summary

Nymox Pharmaceutical Corp (NYMXF) is a clinical-stage biopharmaceutical company primarily engaged in the research and development of targeted therapies for the aging male population. The company’s revenue model is centered on the future commercialization and licensing of its lead drug candidate, NYMOZARFEX (Fexapotide Triflutate), a first-in-class injectable treatment for benign prostatic hyperplasia (BPH) and low-grade localized prostate cancer. Currently, the firm operates through a single reportable segment focused on R&D, supplemented by modest revenue from its proprietary diagnostic products, NicAlert and TobacAlert, which measure tobacco exposure. Nymox positions itself as a disruptive alternative to traditional BPH treatments, competing directly with established pharmaceutical giants such as Eli Lilly (Cialis), GlaxoSmithKline (Avodart), and Astellas Pharma (Flomax), as well as medical device firms like Teleflex (UroLift). Its competitive edge lies in providing a minimally invasive, long-term injectable solution that avoids the systemic side effects and surgical risks associated with current standards of care. Leadership is spearheaded by Founder, President, and CEO Dr. Paul Averback, who also serves as the Chief Science Officer and holds a significant 34% ownership stake. Dr. Averback brings over three decades of experience in neuropathology and pharmaceutical development, having authored extensive research on Alzheimer’s and prostate health. The executive team includes Patrick Doody, who serves as Vice President and General Counsel, and Dr. Suresh Kalbag, the Director of CMC Operations, who oversees manufacturing and process development with a pedigree that includes senior roles at Genentech and Novartis. The Board of Directors features notable figures such as James G. Robinson, CEO of Morgan Creek Productions, and Professor David Morse, a renowned expert in biochemistry and genomics. Despite a period of shareholder activism and legal disputes in 2023-2024, the incumbent leadership remains focused on navigating the regulatory resubmission of NYMOZARFEX with the UK’s MHRA and other global health authorities as of early 2026.